Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase for Tumor Lysis Syndrome
NCT00651911Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jul 2003
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rasburicase in tumor lysis syndrome (TLS), sponsored by Sanofi. Primary endpoint: Uricolytic response to rasburicase treatment at 5 weeks. Started Jul 2003; status: completed.
02
Drugs
rasburicase
03
Conditions
tumor lysis syndrome (TLS)
Beyond the preview
Go deeper on NCT00651911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651911.